Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ALNYthis companyAlnylam Pharmaceuticals, Inc.	$156.13	166.38×	66.01×	14.03×	81.9×	-1017.9%	81.8%	13.5%	8.4%	39.8%	13.7%	0.9%	1.62×	-0.6×	1.99×	2.76×	0.0%	5	3.79	4	A-
ARWRArrowhead Pharmaceuticals, Inc.	$48.01	-2,827.05×	9.9×	5.56×	28.84×	-253.1%	100.0%	11.9%	-0.2%	-0.3%	4.6%	3.4%	0.79×	0.85×	1.1×	4.86×	0.0%	3	2.67	1	D+
IONSIonis Pharmaceuticals, Inc.	$28.90	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
NTLAIntellia Therapeutics, Inc.	$11.84	-2.36×	1.45×	14.4×	-2.3×	-249.6%	76.5%	-651.7%	-609.9%	-61.5%	-57.7%	-36.4%	0.14×	0.16×	0×	5.08×	0.0%	4	2.17	2	C
WVEWave Life Sciences Ltd.	$3.29	-14.05×	5.45×	67.1×	-11.67×	-66.1%	79.3%	-504.1%	-478.3%	-38.8%	-39.0%	-6.5%	0.03×	2.99×	0×	6.47×	0.0%	2	-0.46	2	C
Peer median	—	-23.64×	7.67×	13.9×	-6.99×	-251.3%	88.8%	-272.3%	-259.3%	-50.2%	-25.5%	-4.5%	0.46×	0.5×	0×	4.97×	0.0%	3	1.53	2	—